Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspective

July 18, 2026 updated by: Asmaa Elwan Mohammed Hassan, Mansoura University

Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspective - A Quasi Experimental Study

This study aims to evaluate the impact of using a mobile application-based medication reminder on medication adherence among patients diagnosed with chronic diseases and memory impairment. Adherence to prescribed therapy is a significant challenge for this patient population, often leading to poor health outcomes and increased healthcare costs. From a nursing leadership perspective, innovative digital solutions can play a crucial role in supporting patient self-management. Using a quasi-experimental design, the study will investigate whether a customized mobile reminder system can effectively improve adherence rates and support patients in managing their therapeutic regimens.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Improving medication adherence in patients with chronic illnesses and cognitive decline is a key priority in healthcare management and nursing administration. This quasi-experimental study utilizes a pretest-posttest design to examine the effectiveness of a mobile application-based reminder system designed specifically for patients experiencing memory impairment.

Participants will be selected based on specific inclusion criteria, including being diagnosed with a chronic disease and exhibiting mild-to-moderate memory impairment. Baseline assessments (pretest) will be conducted to measure initial medication adherence levels, patient demographics, and health status. Following the baseline phase, the intervention will be introduced, where participants will utilize the mobile application to receive automated medication alerts and reminders over a specified period. Evaluation (posttest) will be performed post-intervention to analyze changes in adherence rates. The findings are expected to provide insights into how nursing leadership can leverage mobile health (mHealth) technology to design supportive care pathways, enhance patient independence, and reduce clinical complications associated with poor treatment adherence.

Study Type

Interventional

Enrollment (Estimated)

193

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Mona Ahmed Gabr, PhD
  • Phone Number: 201097898593

Study Locations

  • Egypt
    • Dakahlia Governorate
      • Gamasa, Dakahlia Governorate, Egypt
        • Recruiting
        • Outpatient Clinics, Delta University for Science and Technology
        • Contact:
        • Contact:
          • Mona Ahmed Gabr, PhD
    • Kafr el-Sheikh Governorate
      • Kafr ash Shaykh, Kafr el-Sheikh Governorate, Egypt
        • Recruiting
        • Outpatient Clinics, Kafr El-Sheikh Hospital
        • Contact:
        • Contact:
          • Mona Ahmed Gabr, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients diagnosed with one or more chronic diseases requiring regular long-term medication.
  • Patients exhibiting mild-to-moderate memory impairment or cognitive decline as screened by the Mini-Mental State Examination (MMSE).
  • Patients who personally own and are capable of operating a smartphone or have a primary caregiver willing to manage the mobile application.
  • Patients aged 18 years and older.
  • Patients who provide voluntary informed consent to participate in the study.

Exclusion Criteria:

  • Patients with severe cognitive impairment or advanced dementia who cannot interact with mobile technology even with caregiver assistance.
  • Patients with severe acute clinical complications or unstable psychiatric conditions.
  • Patients participating in another concurrent clinical trial or study targeting medication adherence

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mobile Application Group
Participants in this single-group study will receive training on and utilize a customized mobile application-based medication reminder designed to support adherence to their therapeutic regimens.
Device: Mobile Application-Based Medication Reminder
The intervention consists of a mobile application specifically designed to support medication adherence. It features automated push notifications, customized reminder alerts matching prescribed medication schedules, and tracking logs. Participants will be instructed on how to install, configure, and use the application on their personal smartphones. The system is designed to provide immediate prompts to overcome memory-related adherence barriers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medication Adherence (MMAS-8)
Time Frame: Baseline (pre-intervention) and 3 months post-intervention
Medication adherence will be assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). This self-reported tool evaluates patients' behaviors regarding taking their prescribed chronic medications. Total scores range from 0 to 8, where a score of 8 indicates high adherence, 6 to <8 indicates medium adherence, and <6 indicates low adherence.
Baseline (pre-intervention) and 3 months post-intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Medication Adherence: Medication Possession Ratio (MPR)
Time Frame: 3 months post-intervention
Medication Possession Ratio (MPR) will be calculated using pharmacy refill records to determine the proportion of time the patient has access to their prescribed medication during the study period. Total scores will range from 0 to 1 (or 0% to 100%), with higher values indicating better adherence.
3 months post-intervention
Objective Medication Adherence: Proportion of Days Covered (PDC)
Time Frame: 3 months post-intervention
Proportion of Days Covered (PDC) will be assessed using pharmacy refill records to measure the percentage of days the patient covered their prescribed medication dosage over the study duration. Total scores will range from 0 to 1 (or 0% to 100%), where higher values reflect superior medication adherence.
3 months post-intervention
Cognitive Function Status (MMSE)
Time Frame: Baseline
Cognitive impairment levels will be screened using the Mini-Mental State Examination (MMSE) to classify the severity of cognitive/memory impairment among participants.
Baseline
Perceived Nursing Care and Leadership Support
Time Frame: 3 months post-intervention.
Evaluated using the Nursing Care and Leadership Support Assessment Tool to measure patient satisfaction and perception of the supportive role played by nursing leadership during the application-based program.
3 months post-intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mansoura University

Collaborators

Al-Azhar University
Delta University for Science and Technology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 10, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

July 14, 2026

First Submitted That Met QC Criteria

July 18, 2026

First Posted (Actual)

July 21, 2026

Study Record Updates

Last Update Posted (Actual)

July 21, 2026

Last Update Submitted That Met QC Criteria

July 18, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DFM-IRB 00012367- 26-04-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared to ensure the confidentiality and privacy of the patients' medical records and personal information.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Disease

Clinical Trials on Mobile Application-Based Medication Reminder

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe